Related Experiment Videos
[Single-agent trial with epirubicin in hematological malignancies]
Gan No Rinsho. Japan Journal of Cancer Clinics
|February 1, 1987
Summary
Epirubicin showed efficacy in lymphoid malignancies, with partial remission in acute lymphoblastic leukemia (ALL) and complete/partial remission in non-Hodgkin lymphoma (NHL). Stomatitis was a notable side effect in acute leukemia patients.
Area of Science:
- Hematology
- Medical Oncology
Context:
- Hematological malignancies pose significant treatment challenges.
- Epirubicin is an anthracycline chemotherapy agent.
Purpose:
- To evaluate the efficacy and safety of epirubicin in patients with hematological malignancies.
- To assess response rates in specific subtypes like ALL, AML, and NHL.
Summary:
- Ten evaluable patients with hematological malignancies received epirubicin.
- Partial remission (PR) was observed in 25% of ALL patients previously treated with anthracyclines.
- Complete remission (CR) in one B-cell lymphoma and PR in one ATLL patient (50% CR+PR) were noted in NHL.
- No remission was achieved in AML patients.
- Stomatitis was the primary observed side effect.
Impact:
- Epirubicin demonstrates potential efficacy in treating lymphoid malignancies.
- Further investigation is warranted to confirm these findings and optimize treatment strategies.